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ABSTRACT
The outbreak of COVID-19, the disease caused by SARS-CoV-2, continues to affect millions of people
around the world. The absence of a globally distributed effective treatment makes the exploration of
new mechanisms of action a key step to address this situation. Stabilization of non-native Protein-
Protein Interactions (PPIs) of the nucleocapsid protein of MERS-CoV has been reported as a valid strat-
egy to inhibit viral replication. In this study, the applicability of this unexplored mechanism of action
against SARS-CoV-2 is analyzed. During our research, we were able to find three inducible interfaces of
SARS-CoV-2 N protein NTD, compare them to the previously reported MERS-CoV stabilized dimers, and
identify those residues that are responsible for their formation. A drug discovery protocol imple-
mented consisting of docking, molecular dynamics and MM-GBSA enabled us to find several com-
pounds that might be able to exploit this mechanism of action. In addition, a common catechin
skeleton was found among many of these molecules, which might be useful for further drug design.
We consider that our findings could motivate future research in the fields of drug discovery and
design towards the exploitation of this previously unexplored mechanism of action against COVID-19.
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Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-
CoV-2), the causative agent of COVID-19, is a positive-sense
single-stranded RNA virus that belongs to the b genus of the
Coronaviridae family. The SARS-CoV-2 virion consists of at
least four (4) structural proteins: Spike (S) protein, membrane
(M) protein, envelope (E) protein, and nucleocapsid (N) pro-
tein (Li et al., 2020). These proteins, along with other non-
structural ones, have been identified as important drug tar-
gets (Dong et al., 2020), and have been widely investigated
since the pandemic started. However, despite the efforts of
the global community, only few treatments have shown posi-
tive outcomes in their clinical trials, with their worldwide
accessibility remaining as a challenge.
Among these main targets, N protein is a major structural
protein divided into three domains, namely an N-terminal
RNA binding domain (NTD), a poorly structured central Ser/
Arg (SR)-rich linker, and a C-terminal dimerization domain
(CTD) (Chang et al., 2013). This protein has been recognized
as an important drug target against CoVs since it plays sev-
eral crucial functions in the viral cycle, such as packaging the
RNA genome into ribonucleoproteins (RNP), modulating host
cell metabolism and regulating viral RNA synthesis during
replication and trascription (Chang et al., 2014).
Recent studies showed that the stabilization of non-native
Protein-Protein Interactions (PPIs) between these N terminal
domains (NTD) in MERS coronavirus is a valid strategy to halt
viral replication (Amin & Jha, 2020; Ghosh et al., 2020; Lin
et al., 2020). However, to date no study has evaluated the
applicability of exploiting this mechanism of action against
COVID-19.
Modulation of PPIs by small molecules is an emerging
and versatile strategy in drug development. The direct stabil-
ization of these type of interactions is conceptually challeng-
ing since it requires the simultaneous targeting of more than
one protein within the complex. Even though there are
numerous examples of small molecules (especially natural
products) that relay their biological activity on this type of
interactions (Andrei et al., 2017), very few studies have
focused on modeling PPIs for drug design.
In the first part of this work, the stabilization of the
reported MERS-CoV non-native nucleocapsid homodimers is
analyzed using molecular dynamics and end-point MM-GBSA
energy calculations, with results in good correlation with the
reported experimental data. Then, a proposed protocol led
to the identification of a privileged scaffold that may be
used for further rational drug design. In addition, two already
effective drugs against SARS-CoV-2, Ruxolitinib and
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Sorivudine, were also found between the potential active
compounds, and therefore this alternative mechanism of
action might explain part of their activity. We believe that
the contributions made in this research might be useful in
future drug design, not only for this particular mechanism of
action, but also for any study that aims for PPIs stabilization
by small molecules.
2. Methods
A general scheme of the protocol is presented in Figure 1.
2.1. Mers-CoV interface preparation
The published MERS-CoV homodimers PDB ID 6KL5 and 6KL6
were rebuilt for the initial analysis. Missing residues were
added using 4UD1 as template. The isolated system was
named IF-MERS-CoV whereas ligand-bonded dimers were
called P1/IF-MERS-CoV and P3/IF-MERS-CoV (ligands were
named as in the Hou’s article (Lin et al., 2020)).
2.2. Sars-CoV-2 interface preparation
In order to obtain inducible homodimer interfaces between
NTD N protein monomers, a crystal tetramer was selected
(PDB ID 6VYO). This structure consists of four monomers sta-
bilized with Zn2þ cations. The selected interfaces were
covered by the union of chains A/B (IF-1) and chains B/C (IF-
2), which are equivalent to the interface generated by chains
C/D and D/A, respectively. Because there are missing resi-
dues (UniProt ID P0DTC9), some of them close to the inter-
face, the dimers were rebuilt by superimposing a monomeric
experimental structure obtained by solution NMR (PDB ID
6YI3). This structure include hydrogen atoms, which
were conserved.
Furthermore, an additional interface was generated using
the same methodology on 6KL5 dimer structure, an X-ray
non-native dimer corresponding to the MERS-CoV N protein
(Lin et al., 2020). This dimer was called IF-3 (see Figure 2).
Finally, these homodimers were subjected to a minimiza-
tion, heating and NPT equilibration process in order to gen-
erate small cavities capable of harboring a stabilizing ligand.
2.3. Sequence alignment and comparison
MERS-CoV, SARS-CoV and SARS-CoV-2 Nucleocapsid proteins
sequences (Uniprot IDs: R9UM87, P59595 and P0DTC9
respectively) were aligned and compared using JalView
2.1.11.0 software (Waterhouse et al., 2009).
2.4. Molecular docking studies
Compounds from DrugBank 5.1.6 database (Wishart et al.,
2006) were screened against the selected dimer interfaces.
Figure 1. General Scheme of the protocol developed for the present study.
Figure 2. Selected homodimer interfaces to be stabilized: IF-1 and IF-2 built from 6VYO, and IF-3 from 6KL6 structure. Image created using Pymol.
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The protonation state of each ligand at pH 7.4 was based on
analysis using FixpKa, included in QUACPAC 2.0.2.2 (OpenEye
Scientific Software) and its conformers were generated using
Omega (Hawkins & Nicholls, 2012). A docking region in each
interface was selected using Make Receptor tool, included in
the OEDocking 3.4.0.2 suite, OpenEye (McGann, 2012).
Parameters were kept to their default values. Molecular dock-
ing was performed to find and score binding poses by
means of FRED software, included also in the OEDocking
suite. Parameters were kept to their default value. Based on
the results, the Phenol-Explorer database (Neveu et al., 2010)
was included to be treated with this same docking protocol.









where CDSi is the consensus docking score of compound i,
SiðÞ and hSðÞi are score of compound i and average score in
IFn (IF-1, IF-2, IF-3 interface) and RNA interaction resi-
dues docking.
2.5. Molecular dynamics (MD) simulations
MD simulations were performed on complexes of the
selected ligands and dimers. Since these systems have a
positive net charge, chlorides were added as counterions
with Leap module to achieve electroneutrality. The neutral-
ized complexes were immersed in a box of TIP3P waters
which extended up to 15 from the complex. Dimers were
described using the Amber14SB force field (Maier et al.,
2015). Ligand topologies were built using the Generalized
Amber Force Field (GAFF) (Wang et al., 2004) with charges
derived from RESP, which were calculated with Antechamber
module and Gaussian03 (Frisch, 2004). Leap and
Antechamber (Wang et al., 2006) are included in the package
AmberTools 19.0 (Case, 2019).
All MD simulations were run using the NAMD 2.13 soft-
ware (Phillips et al., 2005). The van der Waals interaction cut-
off distances were set at 12 and long-range electrostatic
forces were computed using the particle mesh Ewald sum-
mation method with a grid size set to 1.0. The 1-4 contribu-
tions were multiplied by a factor of 0.83 to match the
AMBER force field requirements. The complexes were submit-
ted to a series of minimization stages (including hydrogens,
waters, residue side chains and the complete system) of
1,00,000 maximum steps each, and heating from 0 to 310 K.
For equilibration/production simulations, constant tempera-
ture (310 K) was maintained using Langevin dynamics with a
damping coefficient of 5 ps– 1, while pressure was kept con-
stant at 1 atm through the Nose-Hoover Langevin piston
method with a decay period of 200 fs and a damping time
constant of 100 fs. A time step of 1 fs was used along
molecular mechanics. Bonds involving H atoms of waters
were constrained using the SHAKE algorithm. Cationic
Dummy Atom method (Pang, 2001) was used when the
Zn2+cation is included in the system.
RMSD plots were depicted to determine the convergence
and stability of simulations and are available in the
Supplementary Information (Tables S3-8).
2.6. Total interaction energy calculations
In order to quantify the dimer stabilization exerted by the
ligand, two stabilization components were considered: lig-
and-dimer and monomer-monomer interactions. The sum of













These energies were calculated using free energy decom-
position analysis, which was performed using a pairwise
energy decomposition scheme (idecomp option 3) with the
MMPBSA.py module (Miller et al., 2012).
In this scheme, interactions are decomposed by specific
residue pairs by including only those interactions in which
one atom from each of the analyzed residues is participating,
following the work of Gohlke et al. (Gohlke et al., 2003) A
single trajectory based on 50 snapshots was taken from the
last 5 ns portion (100 ps interval) of the MD production tra-
jectories. The entropic change of the complexes was
assumed constant to reduce computational cost. The solv-
ation free energy (DGsolv) was separated into polar and non-
polar contributions. The polar contribution to DGsolv was cal-
culated using the generalized Born (GB) model implemented
in MMPBSA.py module: igb ¼ 2/mbondi2 radii sets and igb
¼ 8/mbondi3 radii sets as selected models for ligand/protein
and monomer/monomer interactions, respectively. Further,
this decomposition scheme allowed us to assign the percent-
age of the ligand-dimer interaction to each monomer, and
thus ensure that there is a balanced distribution. CPPTRAJ
(Roe & Cheatham, 2013) and ParmEd programs, included in
AmberTools, were used for trajectory handling.
3 Results
3.1. Interface selection and analysis
3.1.1. Analysis of the reported MERS-CoV interface
In order to understand, model and compare the behavior of
PPIs between the nucleocapsid NTD of SARS-CoV-2, a com-
putational analysis of the previously reported (Lin et al.,
2020) non-native MERS-CoV Nucleocapsid NTD dimers
was conducted.
This was accomplished by performing molecular dynamics
simulations in the reported ligand-bonded dimers (P1/IF-
MERS-CoV and P3/IF-MERS-CoV) and the isolated interface
(IF-MERS-CoV). All of them proved to be stable systems,
since equilibrium was reached in all cases. TIE calculations
correlated with the activities previously reported (P3,
EC50¼ 32 lM and P1, EC50> 100lM) and also the P3/IF-
MERS-CoV complex proved to be more stable than the iso-
lated dimer (see Table 1). Moreover, in the case of P3 ligand,
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per-residue decomposition analysis showed also excellent
correlation between the reported ligand-dimer interacting
residues and the ones with the strongest interaction in our
simulations. However, this was not accomplished in the case
of P1, since during the trajectory the pose of the ligand
changes (Figure S4). This can be understood considering the
lower number of interactions reported in comparison with
P3, which also explains the differences in the EC50 values.
Per-residue decomposition analysis for the ligand-free IF-
MERS-CoV showed some key interactions between both
monomers which contribute to the system stability
(Figure 3). A:Gly105/B:Asn68 and A:Gly103/B:Thr70 are the
two strongest pair interactions and Gly103, Thr104, Asn138
of chain A and Thr134 of chain B presented significant inter-
actions with more than one residue of the other monomer.
It is important to mention that the added highly mobile
amino acid sequence introduced some uncertainty to these
energy calculations, and their residues were excluded in
these analyses.
Sequence comparison between the MERS-CoV nucleocap-
sid protein and its analog in SARS-CoV-2 revealed that there
is only 48,42% of identity between them (see Figure S1), sug-
gesting that the active ligands in MERS-CoV were unlikely to
be effectively repurposed in SARS-CoV-2.
3.1.2. Sars-CoV-2 ligand-free interfaces analysis
The stabilization of PPIs with small molecules is a challenging
task that begins with the accurate selection of the interfaces
that might be stabilized. A numerous amount of interfaces
can be built with two monomers of the same protein, but
not all of them are capable of being induced by small mole-
cules. As mentioned in the methodology section, three inter-
faces were built relaying on experimental information: IF-1
and IF-2, which were reported in a non-native tetramer crys-
tal structure including a Zn2þ cation, and IF-3, which was
built by homology modelling of the previously analyzed
MERS-CoV interface.
Molecular dynamics on the three ligand-free interfaces
were performed. These simulations showed that the only sta-
ble system was IF-1, with a TIE of 91 kcal/mol which is a
similar value to the one obtained for the IF-MERS-CoV
Figure 3. Per-residue decomposition analyses of the ligand-free interfaces.
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interface. On the other hand, the TIE values of IF-2 and IF-3
were weaker than the previous ones, as expected.
Per-residue energy decomposition for these interfaces
showed that, when comparing the two stable systems with
the unstable ones, the first ones present a higher number of
strong interactions (Figure 3). In the case of IF-1 three
important pair interactions can be observed, these are
B:Asp101/A:Lys196, B:Asp38/A:Lys263 and B:Thr33 with
A:Ser270 and A:Gly272. The contribution to the stability pro-
vided by these residues should be considered in future drug
design, since their blockage may act against dimer
stabilization.
3.1.3. IF-1 and IF-2 and their interaction with Zn2þ
With the intention of understanding the role played by Zn2þ
cation in the crystal structure, it was incorporated to IF-1
and IF-2 dimers. Molecular dynamics simulations and TIE cal-
culations showed that this cation is able to stabilize both IF-
1 and IF-2 dimers (see Table 1), verifying that these two
interfaces can be effectively induced. This discovery might
contribute to the understanding of Zn2þ potential thera-
peutic action against COVID-19, since it has aroused interest
during the pandemic due to its medicinal properties
(Derwand & Scholz, 2020) and has been proposed in many
clinical trials.
3.2. Repurposed drugs as stabilizers
Once the interfaces were selected and the pockets gener-
ated, molecular docking calculations with both investiga-
tional and approved DrugBank’s databases on all the
interfaces were performed. At first, the high mobility of these
systems seemed incompatible with the rigid nature of stand-
ard docking calculations. To address this situation, the com-
pounds were ranked according to a consensus docking score
(CDS), constructed from the relative docking position of each
compound in each interface. Another important issue was
that each system was being considered as equally probable
to be induced, which was not necessarily true. Since RNA
assembly is the main function of this protein, a good strat-
egy to solve this problem would be to prioritize those
ligands capable to interact with the residues involved in this
process, which had already been described in literature
(Kang et al., 2020). With this in mind, a fourth system cen-
tered on those residues was added to the previous consensus
docking score ranking (Table S1, Column “Score RNA and
Pos. RNA”).
Rational manual selection of the best candidates was
made. For this task, the best approved ligands were given
priority over the investigational ones, and those compounds
that had a top score in any of the interfaces were also con-
sidered, even if their consensus ranking was not the best.
With this strategy, 13 initial compounds were selected (Table
S1) for molecular dynamics.
Stabilization was accomplished if ligand, interface-forming
residues and protein backbone RMSD reached a plateau, and
also if the compound showed balanced interactions with res-
idues from both monomers, characterized with MM-GBSA
energy decomposition.
These simulations showed that several compounds were
able to effectively stabilize one or more of the studied inter-
faces (see Table S9, and Figure S3). Moreover, we observed
that those compounds selected because of their higher CDS
behaved better as stabilizers rather than the ones selected
because of their good performance in only one of the inter-
faces. However, we noticed that positively charged ligands
were not able to stabilize any of the interfaces, which is in
accordance with the highly positive charge of both mono-
mers reported in the literature (Kang et al., 2020).
The lack of experimental data makes it very difficult to
establish a threshold and select the most promising com-
pounds from this list. Therefore, we believe that it is very
well justified to use the values observed in P3/IF-MERS-CoV
as reference, even though they belong to a different system.
From this list, Ruxolitinib is already being tested in several
clinical trials against COVID-19, and some results proving its
effectiveness have been published (Koschmieder et al., 2020;
La Rosee et al., 2020). In our simulations, this molecule was
able to stabilize IF-1 and IF-2, with a TIE of 81 and
114 kcal/mol respectively. As can be observed in Table 2,
this last energy value is 12 kcal/mol more stable compared
to P3/IF-MERS-CoV, the active ligand in MERS-CoV. Although
it is believed that this molecule’s effectiveness relays on JAK
inhibition, our results suggest that part of its potency may
be explained by this other mechanism of action. Another
molecule included in this list that is also in clinical trials
against COVID-19 is Quercetin, with results still pending
(ClinicalTrials.gov identifier NCT04377789).
Meanwhile, during the course of our research several
approved drugs where tested in vitro against SARS-CoV-2,
and 100 compounds were identified as inhibitors of viral
Table 1. Decomposed total interaction energy for the studied interfaces calculated with MM-GBSA method.
Interface Ligand/Dimer Interaction (kcal/mol) Mon/Mon Interaction (kcal/mol) TIE (kcal/mol)
IF-MERS-CoV n.a. 96 ± 3 96 ± 3
P1/IF-MERS-CoV 31 ± 2 32 ± 4 63 ± 4
P3/IF-MERS-CoV 41 ± 2 65 ± 3 106 ± 4
IF-1 n.a. 91 ± 5 91 ± 5
IF-2 n.a. 33 ± 5 33 ± 5
IF-3 n.a. 45 ± 4 45 ± 4
Zn2þ/IF-1 101 ± 4 57 ± 4 158 ± 6
Zn2þ/IF-2 101 ± 4 41 ± 6 142 ± 7
Ligand/dimer and monomer/monomer interaction energies were modelled using igb2/mbondi2 radii sets and igb8/mbondi3 radii
sets as selected models, respectively. RMSD plots are available in tables S3-5. n.a.: not applicable.
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replication (Riva et al., 2020). Comparing this list with our
docking results, we noticed that Sorivudine had one of the
top 20 lowest docking scores in IF-1, and therefore it was
considered to run molecular dynamics simulations. These cal-
culations showed that this compound is able to stabilize all
three interfaces, but with a lower TIE than the one obtained
for P3/IF-MERS-CoV in all cases (Table 1). These results sug-
gest that even though this mechanism of action is unlikely
to be the main reason for Sorivudine’s effectiveness, its
potency may also be affected by these type of stabilization.
3.3. Catechins as promising candidates
Our previous docking results showed that most of the mole-
cules with the lowest score were polyphenols, in particular
flavonoids (Table S1). Moreover, molecular dynamics simula-
tions and energy calculations showed that all of these mole-
cules were able to stabilize at least two interfaces. This is
particularly interesting since polyphenolic compounds are
phytochemicals widely spread throughout plants and fruits,
and are known to have medicinal and chemopreventive
activities, for example they are good natural antioxidants.
Moreover, the flavonoid skeleton has been reported as a
privileged substructure for PPIs modulation (Bosc et al.,
2017). Interestingly, a previous study has reported that some
polyphenols inhibit nucleocapsid phosphoprotein’s function
in SARS-CoV (Roh, 2012), which has a 90.52% of identity with
SARS-CoV-2 analog (Figure S2). In this work, Roh compares
the binding affinity of an engineered RNA oligonucleotide
with several polyphenols that block its interaction with the
protein, and therefore inhibit its functionality. Even though
many of these molecules are considered PAINS due to their
catechol substructure and are usually excluded in virtual
screening, we believe that these mentioned literature
together with the high availability of these compounds in
nature makes them relevant to further study their potential
applications in the present context. Consequently, a polyphe-
nol-specific database was added to further study this
possibility.
Molecular docking calculations of these added com-
pounds showed that, among the 378 polyphenolic molecules
in the new database, flavonoids had the lowest consensus
docking scores. Moreover, a good differentiation between
the compounds tested as active and inactive in Roh’s work
was found (Roh, 2012), particularly considering the IF-2
docking score (Table S2). These results motivated the add-
ition of (þ)-Gallocatechin Gallate, (þ)-Gallocatechin,
(-)-Catechin Gallate for further molecular dynamics simula-
tions. Also, (-)-Catechin and (-)-Gallocatechin Gallate were
taken into account for comparison, since they had been
tested in Roh’s work. Finally, despite not being a catechin
itself, Gallic acid 3-O-gallate was also considered since it is a
synthetic precursor of many of the molecules selected, and it
had the second best consensus docking score of all.
Molecular dynamics simulations were in line with our pre-
vious calculations, since all catechins tested stabilized at least
two interfaces (see Table S9). However, this was not the case
for Gallic acid 3-O-gallate, which left the binding site in IF-2
and IF-3. This result highlights the importance of the com-
mon catechin heterocyclic motif for this type of stabilization.
3.4. Total interaction energy calculations and per-residue
decomposition analysis
The final step in this protocol consists of TIE calculations
from MM-GBSA results, shown in Table 1.
Correlation was found between previously known active/
inactive compounds in Roh’s (Roh, 2012) work and the calcu-
lated interaction energies in IF-1 and IF-2. This was not the
case for IF-3, since this interface does not include the resi-
dues that are known to interact with RNA, which were spe-
cifically tested in the cited article. Another important aspect
to notice in this comparison is that dimer stabilization was
not considered in the performed biological assay, which
focuses only in the inhibition of the protein function.
Some stable complexes where the monomer/monomer
interaction term was significantly stronger when compared
with the isolated dimer were observed in the case of IF-2.
Per-residue decomposition showed that many new inter-
action pairs were induced when a ligand was present (Figure
S5), contributing for the complex stability. Even though few
patterns can be observed between the ligands, most interac-
tions involve Arg177 (chain B) and Asn76 (chain C) or resi-
dues close to them. These results suggest that the ligand’s
ability to induce strong interactions between the interface-
Table 2. Information on the selected compounds.
Name/Abbrev. Type
Consensus Docking
Position TIE IF-1 (kcal/mol) TIE IF-2 (kcal/mol) TIE IF-3 (kcal/mol)
Masoprocol Approved, Polyphenol 17 / 23 Dimer Separation 76 ± 5 185 ± 6
Cianidanol Approved, Catechin 38 / 10 142 ± 6 84 ± 6 240 ± 8
(þ)-Gallocatechin Gallate / (þ)GCG Catechin n.i. / 11 134 ± 9 166 ± 8 129 ± 6
(-)-Gallocatechin Gallate / (-)GCG Catechin n.i. / 55 144 ± 7 133 ± 8 Out of binding site
(-)-Epicatechine / (-)EC Investigational, Catechin 18 / 27 154 ± 8 150 ± 6 110 ± 6
(þ)-Gallocatechin / (þ)GC Catechin n.i. / 8 139 ± 7 120 ± 5 113 ± 6
(-)-Epigallocatechin / (-)EGC Catechin 3 / 7 95 ± 8 103 ± 7 185 ± 6
Quercetin Flavonoid 27 / 59 127 ± 6 88 ± 5 Dimer Separation
(-)-Catechin Gallate / (-)CG Catechin n.i. / 32 130 ± 6 162 ± 8 113 ± 5
(-)-Catechin / (-)C Investigational, Catechin n.i / 46 127 ± 5 100 ± 7 125 ± 5
(-)-Epigallocatechin Gallate / (-)EGCG Investigational, Catechin 22 / 79 118 ± 7 150 ± 6 116 ± 5
Ruxolitinib Approved 26 / 18 88 ± 5 114 ± 5 Out of binding site
Sorivudine Approved 219 / 289 95 ± 7 78 ± 5 89 ± 6
An extended table is found in Supplementary information. RMSD plots are available in Tables S6-8. Consensus Docking position for compounds of DrugBank/
DrugBankþ Explorer-Phenol databases. n.i.: not included.
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forming residues is an important aspect to take into account
when aiming for PPIs stabilization.
Energy decomposition is presented in Figure 4. In these
graphics, the most important ligand/residue interactions for
each interface can be easily observed. Ligands with the
strongest ligand/dimer interactions can be visualized in
Figures S6-13. A possible strategy to analyze these results in
IF-1 and IF-2 is to focus on those residues that are known to
interact with RNA (Kang et al., 2020).
Focusing on these residues in IF-1, it can be seen that
His59, Arg92, Ile94, Ser105 and Tyr172 from chain A, and
Arg149 from chain B, are part of this binding site (Figure 4).
Even though few patterns can be observed, (-)EGCG, (-)CG,
(-)EC and (-)C showed strong interactions with many of these
key residues, whereas the other ligands did not. Finally, most
compounds showed a remarkable interaction with Glu174
(chain B), which proved to be an important residue for this
dimer stabilization.
On the other hand, the number of RNA-binding residues
in IF-2 is slightly higher. In its pocket, Thr57, His59, Arg92,
Ile94, Ser105, Arg107, Tyr172 from chain B showed significant
interaction with many of these compounds, especially with
those that had a lower TIE value. Moreover, when comparing
these results with the activities measured in Roh’s work, it
can be observed that the active compounds (-)GCG and
(-)CG interact significantly better with these residues in com-
parison with the inactive molecules, (-)C and Quercetin. This
result could explain the differences between their reported
biological activities. Finally, similar to IF-1, Glu174 shows a
strong interaction with those ligands with better perform-
ance, highlighting its crucial role in the stabilization of
both complexes.
Lastly, IF-3 proved to be a completely different interface
than the previous two. No RNA-binding residues are found in
its pocket, but others turned out to be important for its sta-
bilization. These are: Gly44, Arg88, Asp144 from chain A and
Asp81, Asp82 from chain B. In addition, some of the best sta-
bilizing ligands in this system, such as Cianidanol and
Masoprocol, showed very weak ligand/dimer interaction in
the previous two interfaces, which can be explained due to
the differences between the interface-forming residues.
4. Conclusions
A computational analysis of the stabilization of non-native
PPIs of SARS-CoV-2 N protein as a potential mechanism of
action against COVID-19 is provided. A first comparison with
MERS-CoV enabled us to explore its applicability towards
SARS-CoV-2, where three inducible interfaces were built
based on experimental data. Consequently, a drug discovery
protocol was developed and applied with a drug repurpos-
ing approach, which allowed us to identify the main residues
that build each interface. In addition, potential candidates
that might take advantage of this mechanism were found,
many of them with a common catechin skeleton that might
be useful for further drug design. Even though further
in vitro testing is needed to confirm these findings, we
believe they provide valuable insights into this mechanism
of action that may promote future research in the fields of
drug discovery and medicinal chemistry.
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Figure 4. Per-residue decomposition analyses for selected compound of ligand-dimer energy component. The rows are ordered according to the total ligand-dimer
contribution, decreasing downwards. In addition, the residues that interact with RNA, according to Kang et al. (Kang et al., 2020), are highlighted. Compounds full
name are showed in Table 2.
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